Tidal Investments LLC Grows Stock Position in Stryker Corporation $SYK

Tidal Investments LLC increased its stake in shares of Stryker Corporation (NYSE:SYK) by 174.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 111,457 shares of the medical technology company’s stock after purchasing an additional 70,805 shares during the quarter. Tidal Investments LLC’s holdings in Stryker were worth $35,091,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. California State Teachers Retirement System raised its position in Stryker by 30,523.4% during the 2nd quarter. California State Teachers Retirement System now owns 163,395,348 shares of the medical technology company’s stock worth $51,443,391,000 after buying an additional 162,861,784 shares during the last quarter. Norges Bank acquired a new position in shares of Stryker during the fourth quarter worth about $1,822,272,000. Bank of America Corp DE acquired a new position in shares of Stryker during the second quarter worth about $1,404,284,000. Auto Owners Insurance Co raised its holdings in Stryker by 35,047.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock worth $1,024,444,000 after purchasing an additional 2,906,448 shares in the last quarter. Finally, Legal & General Group Plc acquired a new stake in Stryker in the second quarter valued at about $707,212,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Stryker

In other Stryker news, insider Debra King sold 826 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. This represents a 11.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Dylan Crotty sold 441 shares of Stryker stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider owned 6,102 shares of the company’s stock, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 351,267 shares of company stock worth $118,197,701. Corporate insiders own 4.60% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on SYK. Truist Financial raised their price target on Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a report on Friday, July 31st. JPMorgan Chase & Co. dropped their price objective on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Weiss Ratings reissued a “hold (c)” rating on shares of Stryker in a report on Friday, July 31st. Royal Bank Of Canada lowered their price target on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Finally, Citizens Jmp reduced their price objective on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research note on Monday, August 3rd. Eighteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $381.40.

Stryker Trading Down 0.2%

NYSE:SYK opened at $275.99 on Thursday. Stryker Corporation has a 52-week low of $270.85 and a 52-week high of $392.95. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The stock has a fifty day simple moving average of $326.77 and a 200-day simple moving average of $327.62. The company has a market capitalization of $105.86 billion, a PE ratio of 28.60, a price-to-earnings-growth ratio of 1.73 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts expect that Stryker Corporation will post 15.03 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.3%. Stryker’s payout ratio is presently 36.48%.

Stryker Profile

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker’s principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.